article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. OLC, a lanthanum-based phosphate binder, showed efficacy and tolerability in a phase 2 trial, with most patients achieving target serum phosphate levels.

article thumbnail

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Pharmacy Times

3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed.

article thumbnail

Blujepa From GSK

Pharmacy Times

1,2 The most common adverse reactions are abdominal pain, diarrhea, dizziness, flatulence, headache, nausea, soft feces, vomiting, and vulvovaginal candidiasis. The use of gepotidacin in pregnancy and breastfeeding has not been evaluated. It has not been studied in patients younger than 12 years or who weigh less than 40 kg.

article thumbnail

First cell therapy approved for Type 1 diabetes

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Lantidra, the first cell therapy for certain adults with Type 1 diabetes. In some Type 1 diabetes patients, these infused cells can produce enough insulin. Therefore the patient does not need to continue to take insulin by injections or pump to control blood sugar levels.

article thumbnail

MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’

The Pharmacist

Healthcare professionals should also ensure patients are aware of the side-effects of the diabetes and weight loss injections and report any adverse reactions through the Yellow Card reporting scheme, the Medicines and Healthcare […] The post MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’ appeared first on The Pharmacist.

article thumbnail

Polypharmacy Case Study – Sleepers, Diabetes, and More

Med Ed 101

In this polypharmacy case study, we review a medication list and try to identify areas to reduce medications and avoid adverse reactions. EK is a 66-year-old female with a past medical history of insomnia, diabetes, GERD, hypertension, hyperlipidemia, obesity, recurrent UTI, and osteoarthritis.